基于生物标志物聚类识别心力衰竭六种内表型及其对指南导向药物治疗反应的影响
研究利用BIOSTAT-CHF项目中1802例HFrEF患者的92种心血管生物标志物进行无监督聚类分析,识别出6种互斥的内表型,并在813例独立队列中验证。不同内表型在临床特征、预后及对β受体阻滞剂和ACEI/ARB上调至目标剂量的反应上存在显著差异,内表型5未从上调治疗中获得生存获益,内表型2可能从β受体阻滞剂上调中受损,而内表型4和6则获益。
要点
- 基于92种生物标志物聚类可区分6种HFrEF内表型,各内表型临床特征与预后差异显著。
- 内表型5未从ACEI/ARB和β受体阻滞剂上调中获得生存获益(交互P<0.001)。
- 内表型2从β受体阻滞剂上调中可能受损(HR 1.29;95%CI 1.10-1.42),内表型4和6则获益。
核心结论
- 仅基于生物标志物谱的无监督聚类分析可识别6种HFrEF内表型,其在临床特征、结局及对指南导向药物治疗上调的反应上存在显著差异。
研究设计与样本
- 对BIOSTAT-CHF项目中1802例HFrEF患者使用92种已确立的心血管生物标志物进行无监督聚类分析,并在813例独立队列中验证。
主要发现
- 内表型1患者最年轻、症状较轻、NT-proBNP水平最低,全因死亡或心衰住院风险最低。
- 内表型4患者症状和体征更重、NT-proBNP水平更高,全因死亡或心衰住院风险最高(HR 1.4;95%CI 1.1-1.8)。
- 内表型2、3、5患者对β受体阻滞剂上调至目标剂量的耐受性更好(所有P<0.02)。
- 内表型5未从ACEI/ARB和β受体阻滞剂上调中获得潜在生存获益(交互P<0.001)。
- 内表型2从β受体阻滞剂上调中可能受损(HR 1.29;95%CI 1.10-1.42),而内表型4和6获益(所有交互P<0.001)。
临床怎么用
- 生物标志物驱动的内表型分型可能有助于识别HFrEF患者对指南导向药物治疗上调的差异化反应,为个体化治疗提供线索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: We sought to determine subtypes of patients with heart failure (HF) with a distinct clinical profile and treatment response, using a wide range of biomarkers from various pathophysiological domains. METHODS AND RESULTS: We performed unsupervised cluster analysis using 92 established cardiovascular biomarkers to identify mutually exclusive subgroups (endotypes) of 1802 patients with HF and reduced ejection fraction (HFrEF) from the BIOSTAT-CHF project. We validated our findings in an independent cohort of 813 patients. Based on their biomarker profile, six endotypes were identified. Patients with endotype 1 were youngest, less symptomatic, had the lowest N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels and lowest risk for all-cause mortality or hospitalization for HF. Patients with endotype 4 had more severe symptoms and signs of HF, higher NT-proBNP levels and were at highest risk for all-cause mortality or hospitalization for HF [hazard ratio (HR) 1.4; 95% confidence interval (CI) 1.1-1.8]. Patients with endotypes 2, 3, and 5 were better uptitrated to target doses of beta-blockers (P < 0.02 for all). In contrast to other endotypes, patients with endotype 5 derived no potential survival benefit from uptitration of angiotensin-converting enzyme-inhibitor/angiotensin-II receptor blocker and beta-blockers (Pinteraction <0.001). Patients with endotype 2 (HR 1.29; 95% CI 1.10-1.42) experienced possible harm from uptitration of beta-blockers in contrast to patients with endotype 4 and 6 that experienced benefit (Pinteraction for all <0.001). Results were strikingly similar in the independent validation cohort. CONCLUSION: Using unsupervised cluster analysis, solely based on biomarker profiles, six distinct endotypes were identified with remarkable differences in characteristics, clinical outcome, and response to uptitration of guideline directed medical therapy.
引用
- Tromp J, Ouwerkerk W, Demissei BG, et al. Novel endotypes in heart failure: effects on guideline-directed medical therapy. Eur Heart J. 2018. PMID: 30551207. doi:10.1093/eurheartj/ehy712
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。